Skip to main content
Premium Trial:

Request an Annual Quote

NIMH Seeking Collaborators to Develop, Commercialize Protein Quantification Techniques

NEW YORK (GenomeWeb News) – The National Institute of Mental Health’s Laboratory of Neurotoxicology is seeking interested parties to collaborate in a research alliance to develop and commercialize protein quantification techniques using mass spectrometry.
 
NIMH said the technology can be used in basic research, to diagnose disease, or determine amounts of specific marker proteins in heterogeneous mixtures such as blood or urine.
 
The technology, which uses a combination of recombinant DNA technology, fluorescence, proteolytic, and mass spectrometric methods, is currently in the pre-clinical validation phase.
 
Some applications of the technology could include cell signaling, cell cycle function, developing calibration standards for mass spectrometry and non-mass-spectrometric techniques, and in determining post-translation modification of a signature peptide.
 
Investigators interested in finding out more information may view the NIMH announcement here.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.